ACON Aclarion, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1635077 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY46.0%
TTM net income YoY-37.9%
TTM EPS YoY99.7%
Revenue 3-yr CAGR5.4%
Net income 3-yr CAGR—
Margins
Gross margin29.1%
Operating margin-10,789.2%
Net margin-10,260.0%
FCF margin—
EBITDA margin-10,662.3%
Returns
ROE-74.1%
ROA-69.7%
ROIC (approx.)-958.9%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets6.5%
Debt / equity0.00x
Current ratio14.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $75,730 | $45,724 | $75,404 | $60,444 | $60,292 |
| Cost of revenue | $68,902 | $84,658 | $75,728 | $65,298 | $69,175 |
| Gross profit | $6,828 | -$38,934 | -$324 | -$4,854 | -$8,883 |
| R&D expense | $1.03M | $888,766 | $873,336 | $1.07M | $787,850 |
| SG&A expense | $4.12M | $3.61M | $3.25M | $3.99M | $1.83M |
| Operating income | -$7.05M | -$5.51M | -$4.88M | -$5.56M | -$2.95M |
| Interest expense | — | $64,084 | $110,525 | $1.51M | $474,911 |
| Pretax income | -$7.23M | -$6.99M | -$4.91M | -$7.07M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.23M | -$6.99M | -$4.91M | -$7.07M | -$4.95M |
| EBITDA | -$6.82M | -$5.32M | -$4.71M | -$5.42M | -$2.77M |
| EPS (basic) | -13.61 | -7,478.90 | -79,782.00 | -19.61 | -6.58 |
| EPS (diluted) | -13.61 | -7,478.90 | -79,782.00 | -19.61 | -6.58 |
| Weighted avg. shares (diluted) | 532,036 | 943 | 62 | 381,598 | 905,685 |
| Banking | |||||
| Deposits | — | $463,661 | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $12.02M | $463,661 | $1.03M | $1.48M | $452,530 |
| Receivables | $29,680 | $18,326 | $13,270 | $18,569 | $6,280 |
| Current assets | $12.40M | $824,279 | $1.29M | $1.70M | $732,204 |
| PP&E, net | $24,169 | $5,499 | $1,782 | $3,346 | $12,636 |
| Intangibles | $1.25M | $1.29M | $1.17M | $1.21M | $1.14M |
| Total assets | $13.67M | $2.12M | $2.46M | $2.91M | $1.89M |
| Current liabilities | $837,287 | $1.15M | $3.19M | $688,671 | $7.62M |
| Total liabilities | $837,287 | $1.15M | $3.19M | $688,671 | $7.62M |
| Shareholders' equity | $12.84M | $970,057 | -$727,995 | $2.23M | -$12.83M |
| Shares outstanding | 854,371 | 1,370 | 825,459 | 491,345 | 905,685 |
| Cash flow statement | |||||
| Operating cash flow | -$7.16M | -$5.27M | -$3.65M | -$4.95M | -$2.40M |
| Capital expenditure | $21,528 | $5,115 | $0 | — | — |
| Free cash flow | -$7.19M | -$5.28M | -$3.65M | — | — |
| Investing cash flow | -$203,902 | -$321,937 | -$119,522 | -$207,870 | -$102,005 |
| Financing cash flow | $18.95M | $5.03M | $3.31M | $6.19M | $2.94M |
| Depreciation & amortization | $227,406 | $193,139 | $162,670 | $143,622 | $186,388 |
| Stock-based compensation | $105,368 | $287,455 | $456,001 | $1.19M | $177,489 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.